
Allergan has agreed to buy clinical-stage biotech Vitae Pharmaceuticals for $639 million, or $21 a share – more than double …
US biopharmaceutical company Vitae Pharmaceuticals has appointed Christine Brennan chief business officer. She has over 10 years industry experience and …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

